# Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

> **NCT06223568** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 70 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Oropharynx
- Human Papillomavirus Viruses
- Drug Therapy
- Cancer Vaccine

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** PRGN-2009

## Key facts

- **NCT ID:** NCT06223568
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2028-01-10
- **Final completion:** 2028-01-10
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223568, "Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06223568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*